Cheryl L. Potter, PA-C

Cheryl Potter practices at The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System.

Cheryl Potter's NPI, 1275763815, was assigned on July 16, 2009. Cheryl Potter holds Texas license PA05720.

Cheryl Potter's primary practice is The University of Texas MD Anderson Cancer Center, at 1515 Holcombe Blvd, Houston, TX 77030.

Cheryl Potter's primary practice is The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System. The medical group on file is Physicians Referral Service. Dmand AI also links Cheryl Potter to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Cheryl Potter practices, 2 sites in all. Vendor and product names are available with a free account.

Physician assistant is Cheryl Potter's primary specialty in the NPI Registry, under taxonomy code 363A00000X. Cheryl Potter is board certified in certified physician assistant by the National Commission on Certification of Physician Assistants (NCCPA). Cheryl Potter is licensed in Texas.

Dmand AI lists osteoporosis and vitamin d deficiency among the conditions Cheryl Potter treats.

CMS data shows 86 Medicare services from Cheryl Potter across 3 procedure codes in 2024, all of them office visits, for 143 Medicare patients. Medicare paid $4,565 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 143 Medicare patients who saw Cheryl Potter in 2024. The largest group is 65 to 74, with 66 patients. 75% of them have high blood pressure, and 75% have high cholesterol. Their average risk score is 1.62, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Cheryl Potter's median patient age at 72, with 75% women.

In 2024, Cheryl Potter wrote 834 Medicare Part D claims for 211 patients. 57% of them were for generic drugs. CMS names the drug for 695 of them, across 12 drugs with 11 or more claims each, at $356,949 in total drug cost.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Cheryl Potter for performance year 2024, reported as part of a group. Cheryl Potter accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Cheryl Potter as offering telehealth.

CMS Open Payments shows 3 general payments to Cheryl Potter from 3 drug and device companies from 2024 to 2025. Compensation for serving as faculty or as a speaker for a medical education program make up the largest share, 73% of the total. AstraZeneca Pharmaceuticals LP paid the most, $237.